Patents by Inventor Colyn Cain
Colyn Cain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11162140Abstract: The invention provides for a panel for detecting chromosomal abnormalities in a plurality of cells in a cervical sample wherein the panel comprises a plurality of fluorescently labeled probes individually capable of hybridizing to specific chromosomal locations associated with a chromosomal abnormality in patients at risk for a cervical cell disorder. The invention also comprises a fluorescence in situ hybridization (FISH) probe set comprising the plurality of fluorescently labeled probes.Type: GrantFiled: November 7, 2016Date of Patent: November 2, 2021Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20170067123Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: November 7, 2016Publication date: March 9, 2017Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9562270Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: May 27, 2015Date of Patent: February 7, 2017Assignee: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20160153048Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: May 27, 2015Publication date: June 2, 2016Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9080203Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: September 3, 2014Date of Patent: July 14, 2015Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 9051607Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: April 29, 2014Date of Patent: June 9, 2015Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024394Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024393Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20150024395Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: September 3, 2014Publication date: January 22, 2015Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8852865Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: November 1, 2013Date of Patent: October 7, 2014Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140234839Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: April 29, 2014Publication date: August 21, 2014Applicant: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8748099Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: November 1, 2013Date of Patent: June 10, 2014Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140135229Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: NeoDiagnostix IncInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20140135228Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: ApplicationFiled: November 1, 2013Publication date: May 15, 2014Applicant: NeoDiagnostixInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8603746Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3q and/or 5p.Type: GrantFiled: July 21, 2009Date of Patent: December 10, 2013Assignee: NeoDiagnostix, Inc.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Patent number: 8603747Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: GrantFiled: July 21, 2010Date of Patent: December 10, 2013Assignee: NeoDiagnostix, IncInventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20110082049Abstract: A method of screening for the presence and/or extent of a pathology in a subject, the pathology characterized by an abnormal chromosomal component in a cell of the subject, comprising the steps of: contacting a biological sample comprising cell nuclei from said subject with, one or more distinguishable labeled probes directed to at least one chromosomal sequence that characterizes the abnormality under conditions that promote hybridization of the one or more probes to the at least one sequence, automatically obtaining a representation of the one or more distinguishable labels hybridized to the chromosomal sequences, automatically analyzing the distribution and intensity of binding of the one or more labels in the representation to determine the presence and/or extent of an abnormal chromosomal component; and automatically reporting results of the analysis; wherein the steps are carried out without intervention by a human.Type: ApplicationFiled: July 21, 2010Publication date: April 7, 2011Applicant: NEODIAGNOSTIX, INC.Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20100209913Abstract: The invention provides for a diagnostic test to monitor cancer-specific genetic abnormalities to diagnose cervical cell disorders and predict which patients might progress to cancer. Genetic abnormalities are detected by identification in chromosomal copy number of chromosome 3 and chromosome 5 using FISH analysis of probes targeted to 3 q and/or 5p.Type: ApplicationFiled: July 21, 2009Publication date: August 19, 2010Inventors: Gregory Anton Endress, Madhvi Upender, Elizabeth Light, Colyn Cain
-
Publication number: 20080025981Abstract: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying for potential antitumor agents based on their modulation of the expression of these cancer-related genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing cancer using the gene sequences as well as the polypeptide sequences.Type: ApplicationFiled: November 15, 2006Publication date: January 31, 2008Inventors: Paul Young, Reinhard Ebner, Zoe Weaver, Jeffrey Strovel, Stephen Horrigan, Martin Shea, Bernd Weigle, Michael Rieger, Jennifer Rick, Colyn Cain
-
Publication number: 20070059697Abstract: Methods for identifying potential therapeutic agents, such as anti-tumor agents, based on their modulation of the expression of specified genes, especially genes mapping to specific chromosomal regions, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, including detecting changes in levels of gene copy number and/or level of amplification of the said gene, or sets of genes, to detect and/or diagnose the cancer. Methods for detecting or determining functionally related genes, as well as methods for treating cancer based on targeting expression products of such genes, determining genes involved in the cancerous process and the success and/or response rates and survival statistics for cancer patients on treatment are encompassed by the invention.Type: ApplicationFiled: April 15, 2004Publication date: March 15, 2007Applicant: AVALON PHARMACEUTICALS, INCInventors: Jeffrey Strovel, Colyn Cain, Stephen Horrigan, Meena Augustus